Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Emanuela Lovati"'
Autor:
John A. Rudd, Sze W. Chan, Man P. Ngan, Longlong Tu, Zengbing Lu, Claudio Giuliano, Emanuela Lovati, Claudio Pietra
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Externí odkaz:
https://doaj.org/article/f68a76d710fc4a929a561e4f371caa02
Autor:
John A. Rudd, Sze W. Chan, Man P. Ngan, Longlong Tu, Zengbing Lu, Claudio Giuliano, Emanuela Lovati, Claudio Pietra
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Ghrelin has well-known activity to stimulate appetite and weight gain. Evidence suggests that ghrelin may also have effects in reducing chemotherapy-induced emesis via growth hormone secretagogue receptors (GHS-R1A) in the brain. However, it is not k
Externí odkaz:
https://doaj.org/article/ebe3dc66cfcf4d21b60f7f91344ef0ed
Autor:
Stefano Palea, Veronique Guilloteau, Moez Rekik, Emanuela Lovati, Marc Guerard, Maria-Alba Guardia, Philippe Lluel, Claudio Pietra, Mitsuharu Yoshiyama
Publikováno v:
Frontiers in Pharmacology, Vol 7 (2016)
Introduction. Tachykinins potently contract the isolated urinary bladder from a number of animal species and play an important role in the regulation of the micturition reflex. On the guinea-pig isolated urinary bladder we examined the effects of a n
Externí odkaz:
https://doaj.org/article/af796d9088bb492fbe835eb4e51d8d5c
Autor:
John A Rudd, Man P. Ngan, Zengbing Lu, Guy A. Higgins, Claudio Giuliano, Emanuela Lovati, Claudio Pietra
Publikováno v:
Frontiers in Pharmacology, Vol 7 (2016)
Background and Aims: Chemotherapy-induced acute and delayed emesis involves the activation of multiple pathways, with 5-hydroxytryptamine (5-HT; serotonin) playing a major role in the initial response. Substance P tachykinin NK1 receptor antagonists
Externí odkaz:
https://doaj.org/article/7fbbad8ac87848f89b3f836deb5ff427
Autor:
Valdemar Priebe, Emanuele Zucca, Andrea Rinaldi, Claudio Pietra, Eugenio Gaudio, Filippo Spriano, Luciano Cascione, Anastasios Stathis, Francesco Bertoni, Luca Aresu, Giulio Sartori, Afua Adjeiwaa Mensah, Giovanna Damia, Emanuela Lovati, Chiara Tarantelli, Elisa Civanelli
Publikováno v:
Blood Adv
Histone deacetylase inhibitors (HDACis) are antitumor agents with distinct efficacy in hematologic tumors. Pracinostat is a pan-HDACi with promising early clinical activity. However, similar to other HDACis, its activity as a single agent is limited.
Autor:
Igor Odintsov, Ryan C. Cheng, Allan J. Lui, Tom Zhang, Yue C. Lu, Renate I. Kurth, Morana Vojnic, Inna Khodos, Qing Chang, Kevin Chen, Claudio Giuliano, Annalisa Bonifacio, Isao Miyazaki, Elisa de Stanchina, Emanuela Lovati, Marc Ladanyi, Romel Somwar
Publikováno v:
Cancer Research. 83:4007-4007
Background: Vepafestinib (TAS0953/HM06, Vepa) is a 2nd generation RET-selective inhibitor that effectively penetrates the brain, and inhibits the wildtype RET kinase domain (KD) and RET KD mutants (G810, V804, Y806, L730) (presented at AACR-NCI-EROTC
Autor:
Emanuela Lovati, Man P. Ngan, Zengbing Lu, Longlong Tu, Claudio Giuliano, Francis F.Y. Lam, John A. Rudd, Claudio Pietra
Publikováno v:
Br J Pharmacol
BACKGROUND AND PURPOSE: HM01, a novel, orally bioavailable, brain‐penetrating agonist of ghrelin receptors, ameliorates emesis in Suncus murinus. This study compared HM01's activity against motion sickness with that of the less brain‐penetrating
Autor:
Igor Odintsov, Allan J.W. Lui, Kota Ishizawa, Isao Miyazaki, Inna Khodos, Kentaro Wakayama, Morana Vojnic, Connor J. Hagen, Qing Chang, Annalisa Bonifacio, Claudio Giuliano, Elisa de Stanchina, Emanuela Lovati, Emily Cheng, Marc Ladanyi, Romel Somwar
Publikováno v:
Journal of Clinical Oncology. 40:2024-2024
2024 Background: Patients with RET fusion-positive NSCLC have an estimated 25% incidence of CNS metastasis at diagnosis, and up to 40% during disease progression. Effective anti-RET therapy that penetrates the blood-brain barrier is essential to exte
Autor:
Igor Odintsov, Renate I. Kurth, Kota Ishizawa, Lukas Delasos, Allan J.W. Lui, Inna Khodos, Connor J. Hagen, Qing Chang, Marissa S. Mattar, Morana Vojnic, Siddharth Kunte, Annalisa Bonifacio, Claudio Giuliano, Elisa De Stanchina, Emily Cheng, Emanuela Lovati, Marc Ladanyi, Romel Somwar
Publikováno v:
Molecular Cancer Therapeutics. 20:P233-P233
Fusions involving RET receptor tyrosine kinase are a common driver of tumors across different tissue types, such as lung, thyroid, colorectal, soft tissue and others. TAS0953/HM06 (hereby referred to as HM06) is a novel 2ndgeneration RET-specific inh
Autor:
Claudio Pietra, Francesco Bertoni, Eugenio Gaudio, Annalisa Bonifacio, Afua Adjeiwaa Mensah, Filippo Spriano, Emanuela Lovati
Publikováno v:
Molecular Cancer Therapeutics. 18:B009-B009
Background: Pracinostat (SB939) is a class I, II and IV histone deacetylase inhibitor (HDACi), currently in phase 3 in combination with azacitidine for acute myeloid leukemia (NCT03151408). We have reported its strong preclinical activity in lymphoma